Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
Since the outbreak of COVID-19, a variety of vaccine platforms have been developed. Amongst these, inactivated vaccines have been authorized for emergency use or conditional marketing in many countries. To further enhance the protective immune responses in populations that have completed vaccination...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2021.1957401 |
| _version_ | 1818987866188939264 |
|---|---|
| author | Jialu Zhang Qian He Chaoqiang An Qunying Mao Fan Gao Lianlian Bian Xing Wu Qian Wang Pei Liu Lifang Song Yaqian Huo Siyuan Liu Xujia Yan Jinghuan Yang Bopei Cui Changgui Li Junzhi Wang Zhenglun Liang Miao Xu |
| author_facet | Jialu Zhang Qian He Chaoqiang An Qunying Mao Fan Gao Lianlian Bian Xing Wu Qian Wang Pei Liu Lifang Song Yaqian Huo Siyuan Liu Xujia Yan Jinghuan Yang Bopei Cui Changgui Li Junzhi Wang Zhenglun Liang Miao Xu |
| author_sort | Jialu Zhang |
| collection | DOAJ |
| description | Since the outbreak of COVID-19, a variety of vaccine platforms have been developed. Amongst these, inactivated vaccines have been authorized for emergency use or conditional marketing in many countries. To further enhance the protective immune responses in populations that have completed vaccination regimen, we investigated the immunogenic characteristics of different vaccine platforms and tried homologous or heterologous boost strategy post two doses of inactivated vaccines in a mouse model. Our results showed that the humoral and cellular immune responses induced by different vaccines when administered individually differ significantly. In particular, inactivated vaccines showed relatively lower level of neutralizing antibody and T cell responses, but a higher IgG2a/IgG1 ratio compared with other vaccines. Boosting with either recombinant subunit, adenovirus vectored or mRNA vaccine after two-doses of inactivated vaccine further improved both neutralizing antibody and Spike-specific Th1-type T cell responses compared to boosting with a third dose of inactivated vaccine. Our results provide new ideas for prophylactic inoculation strategy of SARS-CoV-2 vaccines. |
| first_indexed | 2024-12-20T19:13:29Z |
| format | Article |
| id | doaj.art-6ca2e1b1c0384e60bd549b6e0ea96bb9 |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-12-20T19:13:29Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-6ca2e1b1c0384e60bd549b6e0ea96bb92022-12-21T19:29:10ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512021-01-011011598160810.1080/22221751.2021.1957401Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccineJialu Zhang0Qian He1Chaoqiang An2Qunying Mao3Fan Gao4Lianlian Bian5Xing Wu6Qian Wang7Pei Liu8Lifang Song9Yaqian Huo10Siyuan Liu11Xujia Yan12Jinghuan Yang13Bopei Cui14Changgui Li15Junzhi Wang16Zhenglun Liang17Miao Xu18National Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaNational Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaSince the outbreak of COVID-19, a variety of vaccine platforms have been developed. Amongst these, inactivated vaccines have been authorized for emergency use or conditional marketing in many countries. To further enhance the protective immune responses in populations that have completed vaccination regimen, we investigated the immunogenic characteristics of different vaccine platforms and tried homologous or heterologous boost strategy post two doses of inactivated vaccines in a mouse model. Our results showed that the humoral and cellular immune responses induced by different vaccines when administered individually differ significantly. In particular, inactivated vaccines showed relatively lower level of neutralizing antibody and T cell responses, but a higher IgG2a/IgG1 ratio compared with other vaccines. Boosting with either recombinant subunit, adenovirus vectored or mRNA vaccine after two-doses of inactivated vaccine further improved both neutralizing antibody and Spike-specific Th1-type T cell responses compared to boosting with a third dose of inactivated vaccine. Our results provide new ideas for prophylactic inoculation strategy of SARS-CoV-2 vaccines.https://www.tandfonline.com/doi/10.1080/22221751.2021.1957401Heterologousprime-boostinactivatedSARS-CoV-2vaccineneutralizing antibody |
| spellingShingle | Jialu Zhang Qian He Chaoqiang An Qunying Mao Fan Gao Lianlian Bian Xing Wu Qian Wang Pei Liu Lifang Song Yaqian Huo Siyuan Liu Xujia Yan Jinghuan Yang Bopei Cui Changgui Li Junzhi Wang Zhenglun Liang Miao Xu Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine Emerging Microbes and Infections Heterologous prime-boost inactivated SARS-CoV-2 vaccine neutralizing antibody |
| title | Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine |
| title_full | Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine |
| title_fullStr | Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine |
| title_full_unstemmed | Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine |
| title_short | Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine |
| title_sort | boosting with heterologous vaccines effectively improves protective immune responses of the inactivated sars cov 2 vaccine |
| topic | Heterologous prime-boost inactivated SARS-CoV-2 vaccine neutralizing antibody |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2021.1957401 |
| work_keys_str_mv | AT jialuzhang boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT qianhe boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT chaoqiangan boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT qunyingmao boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT fangao boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT lianlianbian boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT xingwu boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT qianwang boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT peiliu boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT lifangsong boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT yaqianhuo boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT siyuanliu boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT xujiayan boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT jinghuanyang boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT bopeicui boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT changguili boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT junzhiwang boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT zhenglunliang boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine AT miaoxu boostingwithheterologousvaccineseffectivelyimprovesprotectiveimmuneresponsesoftheinactivatedsarscov2vaccine |